US Patent

US9056116 — Liquid ganaxolone formulations and methods for the making and use thereof

Method of Use · Assigned to Marinus Pharmaceuticals Inc · Expires 2026-11-28 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for making and using liquid formulations of ganaxolone, specifically those with stable particles of a certain size.

USPTO Abstract

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

Drugs covered by this patent

Ztalmy (GANAXOLONE) · Marinus

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3374`	—	Ztalmy

Patent Metadata

Patent number: US9056116
Jurisdiction: US
Classification: Method of Use
Expires: 2026-11-28
Drug substance claim: No
Drug product claim: No
Assignee: Marinus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.